Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait Authors: Robert A. Hegele Published: 2026 ABSTRACT Purpose of reviewBiallelic loss-of-function (LOF) variants in any of five canonical genes – LPL, GPIHBP1, APOA5, APOC2, and LMF1 – cause familial chylomicronemia syndrome (FCS), a rare and severe Mendelian disorder. Heterozygosity for these same variants is far more common but its clinical implications have only recently come into focus. Here, the past 18months of evidence on the monoallelic carrier state across the FCS genes is synthesized.Recent findingsLongitudinal studies of LPL and APOA5 heterozygotes have demonstrated that triglyceride phenotypes vary widely both between individuals and within the same individual over time, ranging from completely normal levels to severe hypertriglyceridemia. Heterozygosity contributes to 15–25% of multifactorial chylomicronemia syndrome (MCS) cases. Mechanistic data implicate dominant-negative effects for some truncating variants and saturation of compromised lipolytic reserve as unifying explanations, rather than simple haploinsufficiency. Common intermediate-effect risk alleles such as LPL p.D36N and p.N318S, and APOA5 p.S19W and p.G185C, behave differently and should not be conflated with rare LOF variants.SummaryThe phenotype of FCS-gene heterozygotes is best understood as a complex trait modulated by polygenic background and secondary factors. This understanding has practical implications for cascade screening, counseling, and selection of patients who may benefit from emerging apolipoprotein C-III–targeted therapies, particularly those in the refractory MCS subgroup. INTRODUCTION Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder of intravascular lipolysis caused by biallelic loss-of-function (LOF) variants in any of five canonical genes encoding lipoprotein lipase (LPL) or its essential cofactors and regulators [1,2]. Affected individuals present with refractory severe hypertriglyceridemia defined as triglyceride levels (≥ 10 mmol/l or ≥ 885 mg/dl), characteristic syndromic features, and a high lifetime risk of acute pancreatitis [1,3]. The clinical and molecular features of biallelic disease have been extensively characterized [1,2]. In contrast, the implications of heterozygosity, that is, the monoallelic carrier state, have until recently been poorly understood. Heterozygosity for FCS-gene pathogenic variants was historically assumed by analogy with familial hypercholesterolemia to confer an intermediate, dose-dependent phenotype [3]. This assumption is now known to be incorrect. Heterozygotes can present anywhere on the spectrum from completely normal lipid profiles to severe hypertriglyceridemia, often within the same individual at different time points [4▪,5▪,6]. Recent longitudinal studies, expanded population sequencing, and emerging mechanistic data have collectively reframed the heterozygous state as a complex trait whose expression depends on polygenic background and secondary metabolic factors. This review synthesizes literature published since 2023 on the carrier state across the five FCS genes, with emphasis on phenotypic variability, mechanistic underpinnings, and emerging clinical implications. Particular attention is paid to the distinction between rare LOF variants – the focus of this review – and common intermediate-effect risk alleles, which are sometimes conflated in the literature but behave very differently. no caption available THE FIVE FCS GENES AND THEIR CARRIER FREQUENCIES The five canonical FCS genes encode the components of the LPL-mediated lipolytic complex at the capillary endothelium [1,2]. The LPL gene itself accounts for 60–80% of FCS cases [2]. The remaining 20–40% are caused by variants in GPIHBP1 (10–15%), encoding the endothelial anchor for LPL; APOA5 (5–10%), encoding apolipoprotein (apo) A-V, an enhancer of LPL activity; APOC2 (1–5%), encoding the obligate cofactor apo C-II; and LMF1 (1–2%), encoding the intracellular chaperone protein lipase maturation factor 1 [1,2]. Population-scale sequencing has revealed that approximately 3–4% of normolipidemic adults carry a rare pathogenic or likely pathogenic variant in at least one of these five genes [6,7]. The frequency rises to roughly 10–15% in cohorts with mild-to-moderate hypertriglyceridemia (formerly hyperlipoproteinemia type 4) [8] and 15–25% in cohorts with severe hypertriglyceridemia (formerly hyperlipoproteinemia type 5) [9], representing a three to five-fold enrichment relative to controls [7–9]. The enrichment is most pronounced for LPL variants [10,11▪], simply reflecting the relative gene contributions to FCS overall and the larger number of pathogenic variants reported in this gene [2,10]. Heterozygotes for GPIHBP1, APOA5, APOC2, and LMF1 LOF variants are individually rare and have been less extensively phenotyped, representing an important data gap [11▪]. Recent contributions have begun to fill this gap from different angles. For instance, aggregated case-level analyses of APOC2 gene variants have shown that approximately one in four heterozygous carriers is symptomatic, with a small fraction manifesting pancreatitis or severe hypertriglyceridemia [12▪]. Also, genetic surveys of Latino severe hypertriglyceridemia cohorts have highlighted unexpected enrichment of LMF1 heterozygous variants relative to other populations [13▪]. LONGITUDINAL PHENOTYPE VARIABILITY A clinically consequential recent insight is that the triglyceride phenotype in FCS-gene heterozygotes varies substantially over time within the same individual, not merely between individuals. Two longitudinal observational studies of patients followed in a single specialized lipid clinic have established this pattern. Perera et al. [5▪] reported longitudinal triglyceride trajectories in heterozygotes for rare pathogenic LPL variants and showed that individual patients moved between normal-triglyceride, mild-to-moderate hypertriglyceridemia (formerly hyperlipoproteinemia type 4), and severe hypertriglyceridemia (formerly hyperlipoproteinemia type 5) phenotypes at different time points across years of follow-up. Some carriers experienced episodic excursions to triglyceride levels above 10 mmol/l, while others remained normolipidemic throughout follow-up despite carrying the identical variant. Excursions were typically associated with weight gain, new-onset diabetes, alcohol use, or initiation of triglyceride-raising medications. An independent Polish whole-exome-sequenced cohort similarly identified LPL variant heterozygotes spanning the full phenotypic range, from normolipidemic through severe and very severe hypertriglyceridemia (triglyceride > 22.6 mmol/l) with recurrent pancreatitis, with secondary factors and age modulating expression [14▪]. It was proposed that a single copy of the wild-type allele offers adequate lipolytic capacity when lipoprotein metabolism is not stressed, but lipolysis becomes insufficient in the context of an increased burden of unfavorable secondary factors [15]. A potential pathophysiological model is shown in Fig. 1. Heterozygous lipolytic deficiency as a complex trait. (a) For each genotype, the dashed line marks the genotype-set ceiling of lipolytic capacity and the filled bar the prevailing metabolic load. Chylomicronemia (hatched) arises when load exceeds the ceiling. Wild-type carriers have ample reserve and remain normal. The heterozygote has a fixed, reduced ceiling: triglyceride is normal under low load but rises to severe hypertriglyceridemia or multifactorial chylomicronemia syndrome as secondary factors accumulate (double-headed arrow), reversing when they are controlled. In biallelic FCS the ceiling is absent, causing chylomicronemia from birth. (b) Longitudinal trajectory of a sample heterozygote. The same individual moves across the normal (< 2), mild-to-moderate (2–9.9), and severe (≥ 10 mmol/l) ranges as secondary-factor burden changes: (1) lean young adult; (2) weight gain and alcohol; (3) new type 2 diabetes; (4) estrogen therapy with pancreatitis; and (5) weight loss plus fibrate. FCS, familial chylomicronemia syndrome; HTG, hypertriglyceridemia; LPL, lipoprotein lipase; MCS, multifactorial chylomicronemia syndrome; TG, triglyceride. A parallel longitudinal study of heterozygotes for APOA5 LOF variants demonstrated essentially identical phenotypic behavior [16▪]. Within-individual variability was substantial, and several patients alternated between normal triglyceride and severe hypertriglyceridemia over the course of follow-up depending on metabolic context. As with LPL LOF variant carriers, the wild-type allele appears to provide sufficient compensation under favorable conditions, but lipolytic reserve is exhausted when secondary factors accumulate. Comparable longitudinal data are not yet available for heterozygotes of the other three less common FCS genes, partly due to their low frequency. Cross-sectional reports suggest a similar pattern, but more systematic and rigorous longitudinal phenotyping is needed. This represents the most important data gap in the field and is a logical priority for future cohort studies, ideally through coordinated international registries given the rarity of these variants. MECHANISTIC CONSIDERATIONS If heterozygosity does not produce a fixed intermediate phenotype, what does it actually do? Three nonmutually exclusive mechanisms have been proposed: haploinsufficiency; dominant negative effects; and saturation of compromised lipolytic reserve [15]. Can simple haploinsufficiency explain the phenotype? If heterozygosity were a straightforward haploinsufficiency state, carriers would be expected to consistently show approximately half-normal LPL pathway function and a correspondingly modest, stable elevation in triglyceride. The observed reality that many carriers are entirely normolipidemic for years and only manifest hypertriglyceridemia when secondary factors intervene, is incompatible with this simple model [4▪,14▪,17]. The wild-type allele is evidently capable of supplying sufficient functional protein under most conditions. Do dominant-negative effects provide a potential explanation? For some truncating APOA5 variants, there is preliminary evidence that the truncated protein is expressed and can interfere with the assembly of wild-type apo A-V onto lipoprotein particles [4▪,17,18]. This dominant-negative model would predict that not all LOF variants are equivalent: nonsense and frameshift variants producing stable truncated proteins may behave differently from variants producing no detectable protein at all. A complementary observation has been made for APOC2, where premature chain-termination variants (nonsense and frameshift) account for a substantial proportion of pathogenic alleles, are associated with more severe biallelic phenotypes than missense variants, and identify the small subset of heterozygous carriers (~25%) who manifest clinical features including pancreatitis and severe hypertriglyceridemia [12▪]. Whether analogous dominant-negative mechanisms are operative in the case of variants in the other FCS genes is not yet established and warrants systematic functional study. Finally, does saturation of compromised lipolytic reserve yield a satisfactory explanation? A unifying model that reconciles the observed clinical data is that heterozygotes possess reduced but generally adequate lipolytic capacity, which can be saturated by physiological or pathological stresses that increase substrate flux into the lipolytic pathway [15,19]. Under this model, an obese heterozygote with type 2 diabetes who consumes alcohol and is taking a medication that can raise triglyceride (see Table 1) has effectively exhausted their reserve and presents with severe hypertriglyceridemia, whereas the same heterozygote at age 25, lean and metabolically healthy, would be normolipidemic. This homeostatic-reserve framework also accommodates within-individual variability over time, since metabolic context fluctuates with age, weight, medication exposure, and intercurrent illness. Table 1Secondary factors that modulate the heterozygous FCS-gene phenotypeCategorySpecific factorsMechanismLifestyleHigh alcohol intake; high dietary fat; sedentary behavior; excess simple sugarsIncreased very-low density lipoprotein substrate; saturation of lipoprotein lipaseMetabolicObesity; insulin resistance; type 2 diabetes; metabolic syndromeIncreased hepatic very-low density lipoprotein secretion; reduced lipoprotein lipase responsivenessEndocrineHypothyroidism; Cushing syndrome; polycystic ovary syndrome; pregnancyHormone-mediated changes in triglyceride synthesis and clearanceRenal/hepaticNephrotic syndrome; chronic kidney disease; hepatic steatosisAltered lipoprotein metabolismMedicationsEstrogens (oral); glucocorticoids; atypical antipsychotics; valproate; protease inhibitors; retinoids; tamoxifen; cyclosporine; L-asparaginaseVariable; many increase very-low density lipoprotein synthesis or impair lipolysisPolygenic backgroundHigh polygenic score for triglycerides; carriage of common intermediate-effect risk allelesCumulative small-effect variants reduce baseline lipolytic reserve and promote secretion of triglyceride-rich lipoproteins Secondary factors that modulate the heterozygous FCS-gene phenotype DISTINCTION OF RARE PATHOGENIC LOSS-OF-FUNCTION VARIANTS FROM COMMON INTERMEDIATE-EFFECT RISK ALLELES It is essential to distinguish rare pathogenic LOF variants – the focus of this review–- from common polymorphisms with intermediate effect sizes. Variants such as LPL p.D36N and p.N318S, and APOA5 p.S19W and p.G185C, occur at allele frequencies of 5–15% in unselected populations and exert triglyceride-raising effects that are smaller than those of rare LOF variants but larger than those of typical genome-wide-association single nucleotide polymorphisms [8,9,20]. These variants are sometimes erroneously reported as pathogenic causes of FCS or chylomicronemia in clinical genetic reports. They are not. They are risk alleles that contribute to polygenic susceptibility and that, like other components of polygenic scores, modify the phenotype of true rare-variant carriers without themselves being causal [8,9,11▪,15]. HETEROZYGOSITY IS SUSCEPTIBILITY, NOT DOMINANT INHERITANCE The recurring observation that some heterozygotes for rare pathogenic FCS-gene variants present with severe hypertriglyceridemia and pancreatitis has periodically led to the suggestion that an autosomal dominant form of hypertriglyceridemia exists alongside the recessive FCS. This framing is inconsistent with the genetic, pedigree, and population data and should be retired. Three lines of evidence argue against a dominant model. First, in multigenerational pedigrees, hypertriglyceridemia does not co-segregate with heterozygous pathogenic variants in the way required of a dominant trait, that is, affected and unaffected relatives carry the same variant, and within-family triglyceride concordance is poor [15]. Second, in unselected populations the same heterozygous variants are present in about 3–4% of normolipidemic adults, far exceeding the population frequency of severe or even moderate hypertriglyceridemia and demonstrating that the variant alone is neither sufficient nor highly penetrant for the phenotype [6–9]. Third, the same individual carrying the same variant moves between normolipidemic, mild-to-moderate, and severe hypertriglyceridemic states across the lifespan as their susceptibility interacts with secondary metabolic factors [5▪,14▪,16▪,20] and possibly polygenic background. This pattern is incompatible with deterministic dominant inheritance but it is entirely consistent with susceptibility plus modifiers. The accurate genetic model is therefore not a second, dominant Mendelian form of hypertriglyceridemia but rather a complex trait in which heterozygosity confers a susceptibility allele of variable penetrance, expressed only when polygenic burden, common intermediate-effect risk alleles, and secondary factors collectively exceed the threshold permitted by residual lipolytic reserve. This distinction matters clinically: it argues against cascade screening based on the assumption of high penetrance, against deterministic counseling of asymptomatic carriers, and against the use of the term “dominant hypertriglyceridemia” in genetic reports, where it can mislead both clinicians and patients [21]. POLYGENIC BACKGROUND AND SECONDARY FACTORS Severe hypertriglyceridemia in adults is now recognized to be predominantly polygenic [2,9,15,19]. Approximately 35–50% of patients with severe hypertriglyceridemia have an elevated polygenic score for triglyceride, often in the absence of any identifiable rare variant. When a rare LOF variant is present in heterozygous state, the polygenic background determines whether and when the carrier crosses into the hypertriglyceridemic range; carriers of both a rare pathogenic variant and a high polygenic score for triglyceride manifest a substantially more severe phenotype, including markedly higher risk of acute pancreatitis, than carriers of either genetic factor alone [20]. The same logic extends to the common intermediate-effect risk alleles, which are themselves components of polygenic risk scores. Secondary factors operate as the proximate triggers (Table 1). The most common, namely obesity, insulin resistance, type 2 diabetes, excessive alcohol intake, pregnancy [22], and a range of triglyceride-raising medications including estrogens, glucocorticoids, atypical antipsychotics, and certain immunosuppressants [1–3], increase substrate delivery to the lipolytic pathway and saturate the compromised reserve characteristic of heterozygotes. Pregnancy is a particularly important trigger in women who carry FCS-gene variants, where physiological estrogen elevation in the third trimester can precipitate severe hypertriglyceridemia and acute pancreatitis [22]. Conversely, control of secondary factors can return a previously hypertriglyceridemic carrier to normal triglyceride levels [23▪], mirroring the within-individual variability observed in longitudinal cohorts. CLINICAL IMPLICATIONS: CASCADE SCREENING AND COUNSELING OF RELATIVES Because FCS is an autosomal recessive condition, the parents and offspring of an FCS proband are obligate heterozygotes, and full siblings have a 50% chance of being heterozygous. The recognition that the heterozygous state is not benign, even though it is not classically Mendelian, has practical implications for cascade screening. Identified heterozygotes should be informed that they are at increased risk of developing hypertriglyceridemia later in life, particularly in the context of weight gain, poor diet, increased alcohol intake, pregnancy, diabetes, or use of triglyceride-raising medications. They should not, however, be told that they have a guaranteed clinical phenotype, since many will remain normolipidemic indefinitely. The framing should be one of conditional risk, analogous to that used for carriers of moderate-penetrance cancer-susceptibility variants [15]. HETEROZYGOSITY AS A CONTRIBUTOR TO MULTIFACTORIAL CHYLOMICRONEMIA SYNDROME Heterozygosity for an FCS-gene variant is identified in 15–25% of patients with multifactorial chylomicronemia syndrome (MCS), the much more common form of severe hypertriglyceridemia [3,9,10,23▪,24▪]. In these patients, the rare variant is typically combined with an elevated polygenic score, common risk alleles, and/or one or more secondary factors. This integrated genetic-and-environmental architecture explains why MCS does not segregate in families in classical Mendelian fashion despite having a clear genetic component, and why related individuals carrying the same heterozygous variant can have very different triglyceride phenotypes [9,23▪,24▪]. THERAPEUTIC RELEVANCE IN THE ERA OF APOC3-TARGETED THERAPY The recent approval of olezarsen and plozasiran for FCS [25,26] has refocused attention on the question of which patients, beyond those with genetically confirmed biallelic disease, may benefit from these agents. A small subgroup of MCS patients – variously described as having refractory MCS, persistent chylomicronemia, or functional FCS – fail to achieve triglyceride below 10 mmol/l despite optimal conventional therapy and remain at high risk of pancreatitis [3,27]. This subgroup, with an estimated population prevalence of approximately 1 in 5500, is enriched for FCS-gene heterozygotes [3], and within heterozygote cohorts, the highest pancreatitis risk is concentrated in those with concurrent high polygenic background, a group identifiable through combined rare-variant and polygenic-score testing [7,20]. Recent CORE-TIMI 72 trial data demonstrate that the pancreatitis-prevention benefit of olezarsen in non-FCS patients is essentially confined to those with triglyceride above 10 mmol/l and prior pancreatitis [28], a phenotype that may overlap substantially with the heterozygote-enriched refractory subgroup. Whether and how heterozygote status should formally enter eligibility criteria for APOC3 inhibition is an open and urgent question. PRACTICAL MANAGEMENT For most identified heterozygotes, management is based on lifestyle counseling (weight maintenance, alcohol moderation, avoidance of triglyceride-raising medications where possible), aggressive control of metabolic comorbidities, and periodic monitoring of fasting lipid panels. Pharmacotherapy with fibrates and prescription omega-3 fatty acids is appropriate for those who develop sustained hypertriglyceridemia, since heterozygotes – unlike biallelic FCS patients – generally retain meaningful LPL activity that responds to these agents [3]. Pregnant heterozygotes for LOF variants warrant proactive monitoring during the second and third trimesters, and women of reproductive age should be counseled regarding alternatives to estrogen-containing contraceptives. UNRESOLVED QUESTIONS AND FUTURE DIRECTIONS Several priorities emerge from the recent literature. First, prospective longitudinal cohorts of heterozygotes identified through cascade screening, before the onset of clinical hypertriglyceridemia, are needed to characterize the natural history of the carrier state and to identify early predictors of phenotypic conversion. Second, functional characterization of the many missense variants currently classified as variants of uncertain significance is essential. As emphasized in recent curation efforts [10], the gap between reported and demonstrably pathogenic variants is large. Third, systematic phenotyping of GPIHBP1, APOC2, and LMF1 heterozygotes, ideally through coordinated international registries, would address the most conspicuous data gap in the field. Fourth, whether selected high-risk heterozygotes, for example, those with recurrent pancreatitis despite optimal conventional therapy, should be considered for APOC3-targeted therapy independently of their genotype label is a question with both scientific and policy dimensions. Finally, the role of epigenetic modifiers, suggested by recent reports of altered DNA methylation at LPL and other loci in patients with persistent chylomicronemia [29▪,30], may help explain residual phenotypic variability not accounted for by sequence variation alone. CONCLUSION Heterozygosity for pathogenic variants in the five canonical FCS genes is a complex trait, best understood as a susceptibility allele of variable penetrance rather than as a dominant Mendelian disease. The phenotype is highly variable both between individuals and within the same individual over time, modulated by polygenic background, common intermediate-effect risk alleles, and a wide range of secondary factors. Simple haploinsufficiency is inadequate as a mechanistic model; dominant-negative effects and saturation of compromised lipolytic reserve are better-supported alternatives. These insights have practical implications for cascade screening, for counseling of carriers about pregnancy and metabolic comorbidities, and for the emerging question of which non-FCS patients may benefit from APOC3-targeted therapies. Continued progress will require longitudinal cohorts, functional characterization of variants of uncertain significance, and coordinated phenotyping of heterozygotes for the rarer FCS genes. Acknowledgements None. Financial support and sponsorship R.A.H. is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Research Chair, and the Martha G. Blackburn Chair in Cardiovascular Research. Conflicts of interest R.A.H. reports consulting fees from Akcea/Ionis, Amgen, Arrowhead, HLS Therapeutics, Medison, Novartis, Pfizer, Regeneron, Sanofi, and Ultragenyx.